The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-02-28

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Previous data have suggested that vitamin D levels may influence cancer development. In particular, several single nucleotide polymorphisms have been described in the Vitamin D receptor( VDR gene), and some polymorphisms are associated with tumor occurrence. For instance, VDR polymorphisms have been related to cancers of the breast, prostate, skin, colon-rectum, bladder and kidney, although with conflicting observations . VDR polymorphisms have also been investigated in the context of some chronic liver diseases, such as chronic hepatitis B, primary biliary cirrhosis and autoimmune hepatitis . In a recent published study, VDR polymorphism may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in patients with chronic hepatitis B.

A significant association of VDR (ApaI) polymorphism with the development of HCC in chronic HCV infection may help to identify those who are at high risk of developing HCC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer

NCT01956864

Cirrhosis Hepatocellular Carcinoma

WITHDRAWN PHASE1

The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List

NCT01575717

Vitamin D Deficiency Hepatocellular Carcinoma

UNKNOWN NA

Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma

NCT02779465

Hepatitis B Carcinoma, Hepatocellular

NOT_YET_RECRUITING PHASE4

Effectiveness of Inactive Vitamin D Supplementation in Non-Alcoholic Fatty Liver Disease Patients

NCT05613192

Non-Alcoholic Fatty Liver Disease

UNKNOWN PHASE3

Different Regimens of Vitamin D in Treatment of Children With Chronic Liver Disease

NCT05717569

Chronic Liver Disease and Cirrhosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatitis C virus (HCV) infection is one of the major public health problems worldwide . Chronic HCV infection is characterized by a high rate of progression to fibrosis, chronic hepatitis, leading to cirrhosis and ultimately to hepatocellular carcinoma (HCC). Early detection is critically important because the most effective treatment for HCC is surgical resection or ablation therapy when the tumour is small. On the other hand, genetic factors can also contribute, particularly gene polymorphisms of inflammatory cytokines and growth factor ligands and receptors . Vitamin D is involved in the metabolism of skeleton as a systemic hormone but also has important roles in the regulation of host immune responses, fibrogenesis and development of cancer through vitamin D receptor (VDR). Previous data have suggested that vitamin D levels may influence cancer development. In particular, several single nucleotide polymorphisms have been described in the VDR gene, and some polymorphisms are associated with tumor occurrence. For instance, VDR polymorphisms have been related to cancers of the breast, prostate, skin, colon-rectum, bladder and kidney, although with conflicting observations. VDR polymorphisms have also been investigated in the context of some chronic liver diseases, such as chronic hepatitis B, primary biliary cirrhosis and autoimmune hepatitis . In a recent published study, VDR polymorphism may be used as a molecular marker to predict the risk and to evaluate the disease severity of HCC in patients with chronic hepatitis B.

A significant association of VDR ApaI polymorphism with the development of HCC in chronic HCV infection may help to identify those who are at high risk of developing HCC.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hepatocellular carcinoma (HCC)

The VDR genotype in 20 HCV cirrhotic patient with HCC

Group Type OTHER

The VDR genotype

Intervention Type OTHER

The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Liver cirrhosis

The VDR genotype in 20 HCV cirrhotic patient without HCC

Group Type OTHER

The VDR genotype

Intervention Type OTHER

The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Control group

The The VDR genotype in 10 healthy individuals as control

Group Type OTHER

The VDR genotype

Intervention Type OTHER

The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The VDR genotype

The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hcv cirrhotic patient with and without Hcc

Exclusion Criteria

* Malignancy other than HCC
* Co-infection with Hepatitis B virus (HBV) and Human immunodeficiency virus (HIV)
* Cirrhosis is due to causes other than chronic hepatitis C

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes